AABB News Explores the Future of Personalized Medicine

Personalized medicine is growing rapidly, and the May issue of AABB News is taking a closer look at two topics within this area: cellular starting material and blood group genotyping.

The issue’s first feature article explores the role that cellular therapy product source may play in the future of immune cell therapies, such as CAR T-cell therapy. The issue’s second feature addresses the benefits and limitations of blood group genotyping compared with more traditional serologic antibody-based methods when the goal is to find the best matched blood for patient who needs a transfusion.

The monthly history feature article discusses how AABB continued to evolve during the 1970s, when it was, according to former President Howard F. Tasswell, MD, “at the vortex of matters important to blood bankers.” As Tasswell described, AABB had grown from a small group of blood banking pioneers to the world leader in the scientific, technical and administrative aspects of blood banking.

Other articles in the issue discuss the recently released fourth edition of Judd’s Methods in Immunohematology; profile James J. Yoo, MD, PhD, who has helped develop tissue engineering technologies that have been translated into clinical treatments for incontinence; and a new grant to the National Blood Foundation from Digi-Trax that will help NBF Scholars attend the 2022 AABB Annual Meeting.